The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

Q1 2025 Management View CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product launches such as WINREVAIR and CAPVAXIVE. Revenue for ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the approval covers the 21-valent ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product launches such as WINREVAIR and CAPVAXIVE. Revenue for Q1 2025 reached $15 ...

Revenues of $15.53 billion rose 1% year over year as higher sales of blockbuster cancer drug, Keytruda, new products like Welireg, Winrevair and Capvaxive and strong performance of the Animal ...